Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Beyond Air, Inc. (XAIR) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/14/2022 8-K Quarterly results
Docs: "BEYOND AIR, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2022 March 31, 2022 ASSETS Current assets Cash and cash equivalents $ 29,829 $ 80,242 Marketable Securities 32,617 - Restricted cash 10,106 9,988 Inventory, net 711 350 Grant receivable 235 322 Other current assets and prepaid expenses 1,581 2,044 Total current assets 75,078 92,945 Licensed right to use technology 1,734 1,837 Right-of-use lease assets 2,265 2,216 Property and equipment, net 2,757 1,995 Other assets 205 207 TOTAL ASSETS $ 82,039 $ 99,199 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable $ 2,006 $ 1,129 Accrued expenses 8,934 8,374 Operating lease liability 348 281 Loan payable, current portion 310 927 Total current liabilities 11,598 10,712 Long-term liabilities Ope...",
"GARDEN CITY, NY and HAMILTON, BERMUDA, November 10, 2022 –"
08/15/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
02/14/2022 8-K Quarterly results
Docs: "BEYOND AIR, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2021 March 31, 2021 ASSETS Current assets Cash and cash equivalents $ 83,468 $ 34,631 Restricted cash 9,239 637 Grant receivable 661 425 Other current assets and prepaid expenses 1,317 1,530 Total current assets 94,684 37,223 Licensed right to use technology 346 375 Right-of-use lease assets 2,299 1,861 Property and equipment, net 1,772 929 Other assets 209 138 TOTAL ASSETS $ 99,311 $ 40,525 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable $ 1,611 $ 1,325 Accrued expenses 4,328 1,805 Operating lease liability 239 113 Loan payable - 557 Total current liabilities 6,178 3,800 Long-term liabilities Operating lease liability 2,162 1,789 Long-term debt, net 200 4,472 Total liabilities 8,..."
11/15/2021 8-K Quarterly results
Docs: "BEYOND AIR, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2021 March 31, 2021 ASSETS Current assets Cash and cash equivalents $ 47,699 $ 34,631 Restricted cash 1,047 637 Grant receivable - 425 Other current assets and prepaid expenses 1,550 1,530 Total current assets 50,295 37,223 Licensed right to use technology 356 375 Right-of-use lease assets 1,769 1,861 Property and equipment, net 1,424 929 Other assets 211 138 TOTAL ASSETS $ 54,056 $ 40,525 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable $ 2,241 $ 1,325 Accrued expenses 4,352 1,805 Operating lease liability 178 113 Loan payable 140 557 Total current liabilities 6,912 3,800 Long-term liabilities Operating lease liability 1,684 1,789 Long-term debt, net 4,539 4,472 Total liabilities..."
08/11/2021 8-K Quarterly results
Docs: "BEYOND AIR, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2021 March 31, 2021 ASSETS Current assets Cash and cash equivalents $ 38,581,386 $ 34,630,682 Restricted cash 1,046,606 637,025 Grant receivable - 425,000 Other current assets and prepaid expenses 1,325,064 1,530,096 Total current assets 40,953,056 37,222,803 Licensed right to use technology 365,158 374,686 Right-of-use lease assets 1,815,351 1,860,885 Property and equipment, net 897,550 928,842 Other assets 137,880 137,880 TOTAL ASSETS $ 44,168,995 $ 40,525,096 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable $ 2,261,777 $ 1,324,988 Accrued expenses 1,695,235 1,804,938 Operating lease liability 187,288 113,141 Loan payable 349,165 556,514 Total current liabilities 4,493,464 3,799,581 ..."
06/16/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
08/12/2020 8-K Quarterly results
06/23/2020 8-K Quarterly results
06/28/2019 8-K Quarterly results
02/14/2019 8-K Quarterly results
Docs: "AIT THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS As of As of December 31, 2018 March 31, 2018 Unaudited ASSETS Current assets Cash and cash equivalents $ 479,700 $ 732,542 Restricted cash 15,912 5,692 Marketable securities 2,573,605 8,304,392 Other current assets and prepaid expenses 85,710 59,249 Total current assets 3,154,927 9,101,875 Licensing right to use technology 495,000 - Property and equipment, net 259,221 253,184 TOTAL ASSETS $ 3,909,148 $ 9,355,059 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities Accounts payables $ 833,732 $ 842,039 Accrued expenses 324,599 1,290,886 Options to be issued to NitricGen 295,000 - Total current liabilities 1,453,331 2,132,925 Liabilities related to warrants - 5,677,934 Long-term liabilities 1,453,331 7,810,859 ..."
08/17/2018 8-K Quarterly results, Appointed a new director
Docs: "Amended and Restated 2013 Equity Incentive Plan",
"AIT Therapeutics Reports Financial Results for First Fiscal Quarter 2019"
03/22/2018 8-K Quarterly results
Docs: ", March 19, 2018 – AIT Therapeutics, Inc. , a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced"
11/06/2017 8-K Quarterly results
Docs: ", November 3, 2017 – AIT Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the three- and nine-months ended September 30, 2017."
08/16/2017 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy